Two Centuries of Weight-Loss Fads Shed Light on Today's GLP-1 Era

Weight-loss trends have come and gone for roughly two hundred years, from tonics and tapeworm diets in the 19th century to today's injectables. A recent analysis published in Psychology Today examines that long arc and asks what it reveals about the current buzz around GLP-1 receptor agonists, the class of drugs best known as Ozempic and Wegovy.

A Familiar Cycle of Hope and Disillusionment

According to the piece, nearly every era has produced a "miracle" solution promising effortless weight loss. Vinegar diets, low-carbohydrate plans, meal-replacement shakes, and appetite-suppressing pills all captured enormous public attention before disappointing results, side effects, or rebound weight gain dimmed enthusiasm. The author argues this pattern matters because GLP-1 medications, while grounded in solid biology, are entering a cultural landscape primed for the same hype.

Why GLP-1s Feel Different

GLP-1 agonists do stand apart from earlier fads in one key respect: clinical trials have shown meaningful average weight loss, often exceeding 15 percent of body weight, a magnitude rarely documented in past interventions. The article notes, however, that outcomes vary widely, and discontinuation frequently leads to weight regain, echoing the long-term struggles seen with earlier approaches.

• 19th-century tonics relied on laxatives and stimulants with little evidence of safety.
• 20th-century meal plans and surgery produced real but hard-to-maintain results.
• GLP-1 drugs combine regulatory approval with growing questions about cost, access, and lasting effects.

Lessons for the Current Era

The author suggests that the long history of weight-loss fads teaches humility. Breakthroughs deserve attention, but so do the social and biological forces that have made dieting so persistently difficult. As researchers continue exploring how these medications fit into broader frameworks that treat obesity as a complex interplay of factors, the piece urges clinicians and patients to weigh benefits against realistic expectations and to pair medication with sustainable lifestyle changes, such as a protein-forward Mediterranean meal plan, rather than rely on any single fix.